The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer.
R. W. Naumann
Consultant or Advisory Role - Endocyte
Research Funding - Endocyte
R. L. Coleman
Consultant or Advisory Role - Endocyte
R. A. Burger
Consultant or Advisory Role - Endocyte
T. J. Herzog
Consultant or Advisory Role - Endocyte
R. Morris
Consultant or Advisory Role - Endocyte
Research Funding - Endocyte
E. A. Sausville
Consultant or Advisory Role - Endocyte (U)
Research Funding - Endocyte
E. Kutarska
Research Funding - Endocyte
S. A. Ghamande
Research Funding - Endocyte
N. Y. Gabrail
Research Funding - Endocyte
S. De Pasquale
Research Funding - Endocyte
E. Nowara
Research Funding - Endocyte
L. Gilbert
Research Funding - Endocyte
J. R. Caton
Research Funding - Endocyte
R. H. Gersh
Research Funding - Endocyte
M. G. Teneriello
Research Funding - Endocyte
W. A. Harb
Research Funding - Endocyte
P. Konstantinopoulos
Research Funding - Endocyte
J. T. Symanowski
Consultant or Advisory Role - Endocyte
C. Lovejoy
Employment or Leadership Position - Endocyte
R. A. Messmann
Employment or Leadership Position - Endocyte